Table 5.

Baseline clinical data and treatment outcomes of patients with 1-month radiological complete response

Variable		Lipiodol-TACE, n = 53	DEB-TACE, n = 52	p
Age (years)	Mean ± sd	63.7 ± 10.1	63.3 ± 10.2	0.84
	Range	38–85	46–85
Gender (male)	Male/female	40/13	44/8	0.24
Cause of cirrhosis	Absent	1 (1.9)	2 (3.8)	0.63
	HCV	32 (60.4)	36 (69.2)
	HBV	8 (15.1)	7 (13.5)
	Alcohol	8 (15.1)	3 (5.8)
	Dysmetabolic	2 (3.8)	3 (5.8)
	Other*	2 (3.8)	1 (1.9)
Child-Pugh	A	49 (92.4)	44 (84.6)	0.39
	B	3 (5.7)	7 (13.5)
	Not applicable	1 (1.9)	1 (1.9)
BCLC stage	0	5 (9.4)	4 (7.7)	0.98
	A	35 (66)	36 (69.2)
	B	12 (22.6)	11 (21.2)
	C	1 (1.9)	1 (1.9)
Tumor extension	Unifocal	30 (56.6)	32 (61.5)	0.61
	Unilobar	44 (83)	43 (82.7)	0.96
Diameter of largest lesion (mm)	Mean ± sd	32.3 ± 17.7	32.6 ± 12.8	0.91
	Range	15–110	10–67
	< 30	27 (50.9)	21 (40.4)
	30-49	18 (34)	24 (46.1)
	50-70	6 (11.3)	7 (13.5)
	> 70	2 (3.8)	0 (0)
Dose of doxorubicin (mg)	Mean ± sd	55.4 ± 14.5	65.1 ± 22.2	0.009
	Range	12–75	30–150
Follow-up duration (months)	Median	30.6	37.5	0.88
	Range	3.4–123.1	6.1–99.6
Time to target tumor progression (months)	Median	11.8	27.8	0.009
	95%CI	9.5–15.8	12.6–NR
Time to tumor progression (months)	Median	12.2	19.7	0.099
	95%CI	9.4–21.2	13.9–30.2
Time to extrahepatic progression (months)	Median	55.1	N.R.	0.37
	95%CI	38.2–N.R.	29.4–N.R.
N. of treatments post-TACE	Mean ± sd	1.60 ± 2.2	0.75 ± 1.20	0.016
Post-TACE Liver transplantation (yes)		6 (11.3)	14 (26.9)	0.04
Overall survival (months)	Median	29.2	35.1	0.49
	95%CI	27.8–44.2	28-53.3

*Other: cryptogenetic (n = 3)

When not otherwise specified, data are given as numbers (and percentages)

NR, not reached